SCHEMBL2934385

SCHEMBL2934385

CC(C)(C)[Si](C)(C)ON(C(=O)O)C1CCC(=O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930260 0.81
SCHEMBL5029566 0.75
SCHEMBL282655 0.68
SCHEMBL329010 0.67 TRIM24 (0.32)
SCHEMBL74024 0.66 PPM1D (0.31)
SCHEMBL2696113 0.65 ATM (0.35)
SCHEMBL5033685 0.63 C5AR1 (0.32)
SCHEMBL24969074 0.62 NFKB1 (0.41)
SCHEMBL16763274 0.62
SCHEMBL420544 0.62 FKBP1A (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046697-B2 Compounds and compositions useful for treating disorders related to NTRK BLUEPRINT MEDICINES CORPORATION 2021-06-29 US disclosed
US-20190169194-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK BLUEPRINT MEDICINES CORPORATION 2019-06-06 US disclosed
US-10017512-B2 Compounds and compositions useful for treating disorders related to NTRK BLUEPRINT MEDICINES CORPORATION (US) 2018-07-10 US disclosed
US-20170066773-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK BLUEPRINT MEDICINES CORPORATION 2017-03-09 US disclosed
EP-1773791-B1 PYRROLOTRIAZINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2010-09-22 EP disclosed
US-7102003-B2 Pyrrolotriazine compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-05 US disclosed
US-20060014745-A1 Pyrrolotriazine compounds BRISTOL-MYERS SQUIBB COMPANY 2006-01-19 US disclosed